Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Agenus Inc. has regained compliance with the minimum bid price requirement of $1.00 set by NASDAQ, ensuring continued listing on the NASDAQ Capital Market. The company focuses on immunology-based therapies for cancer, offering a robust pipeline of immunological agents. Agenus aims to enhance patient populations benefiting from cancer immunotherapy through combination approaches utilizing various antibody therapeutics, adoptive cell therapies, and adjuvants. Headquartered in Lexington, MA, Agenus is committed to advancing treatments for cancer and infectious diseases.

Positive

• Agenus Inc. has regained compliance with NASDAQ's minimum bid price requirement, ensuring continued listing on the NASDAQ Capital Market, providing stability and credibility to investors.

• The company's focus on immunology-based therapies for cancer demonstrates a commitment to addressing critical medical needs and advancing treatments in oncology.

• Agenus' comprehensive pipeline of immunological agents, including antibody therapeutics, adoptive cell therapies, and adjuvants, showcases a diversified approach to combating cancer and infectious diseases.

Negative

• None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and the matter is now closed.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501950583/en/

Investors

917-362-1370

investor@agenusbio.com

Media

917-362-1370

communications@agenusbio.com

Source: Agenus Inc.